Carcinoma: all 6,719 studies

Page 4 of 68. Open to participants first (1,142), then studies with results posted, then the rest; newest registration first within each.

• A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and BevacizumabNot yet recruitingNCT06535737Phase 2
• Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.RecruitingNCT06533267Not applicable
• Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerRecruitingNCT06532279Phase 2
• A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06530914Phase 2
• Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract CarcinomaNot yet recruitingNCT06530823Phase 2
• Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT06530784Phase 2
• Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.RecruitingNCT06529562Not applicable
• Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
• Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular CarcinomaRecruitingNCT06527495Phase 1/2
• Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination TherapyNot yet recruitingNCT06523049Phase 2
• Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial CarcinomaNot yet recruitingNCT06521684
• Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaRecruitingNCT06520319Phase 1
• 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell CarcinomaRecruitingNCT06519760Not applicable
• A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer PatientsRecruitingNCT06518434Phase 2
• Online Adaptive Radiotherapy for Nasopharyngeal CarcinomaRecruitingNCT06516133Phase 3
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06512428Phase 2
• Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingNCT06510660Phase 2
• A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06509997Phase 2
• Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCCNot yet recruitingNCT06508229Phase 2
• Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive CarcinomaNot yet recruitingNCT06505551Phase 1/2
• First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerRecruitingNCT06502743Phase 2
• Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingNCT06498622Phase 2
• Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyNot yet recruitingNCT06496815Phase 4
• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyRecruitingNCT06494995Phase 2
• Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCRecruitingNCT06494943Phase 1/2
• Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsRecruitingNCT06493552Phase 2/3
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
• Lenvatinib Plus DEB-TACE and HAIC Vs. Lenvatinib Plus DEB-TACE for Large HCC with PVTTRecruitingNCT06492395Phase 3
• Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06491134Phase 1
• GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal CarcinomaNot yet recruitingNCT06490341Phase 2
• AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT06489197Phase 2
• A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06487702Phase 2
• Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)Not yet recruitingNCT06483594
• HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II StudyNot yet recruitingNCT06482008Phase 2
• Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam TherapyNot yet recruitingNCT06480903
• Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Not applicable
• A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell CarcinomaNot yet recruitingNCT06478264Phase 2
• Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory CharacteristicsRecruitingNCT06476964Not applicable
• HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06475287Phase 2
• Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCCEnrolling by invitationNCT06475196
• Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular CarcinomaRecruitingNCT06475118Not applicable
• A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell CarcinomaNot yet recruitingNCT06472895Phase 1/2
• Neoadjuvant Radiotherapy for High-risk UTUCNot yet recruitingNCT06472752
• The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving RadiotherapyRecruitingNCT06472739Phase 2
• Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPCRecruitingNCT06472713Phase 2
• Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1
• Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell CarcinomaRecruitingNCT06470217Phase 2
• Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With HematuriaNot yet recruitingNCT06469229
• Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468670Phase 2
• Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468644Phase 2
• Identification of Pattern and Factors Affecting Recurrence in Head and Neck CarcinomaRecruitingNCT06465030
• Anti-cancer Potentiality of Saffron Against Hepatocellular CarcinomaNot yet recruitingNCT06464380Phase 4
• AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMARecruitingNCT06464068Phase 2
• A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Phase 2
• AI Models to Predict Thyroid Cartilage Invasion in Laryngeal CarcinomaRecruitingNCT06463756
• Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingNCT06463665Phase 2
• Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract CarcinomaNot yet recruitingNCT06463548Not applicable
• Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular CarcinomaRecruitingNCT06463522Phase 1/2
• Deep Learning-based sbORN Diagnostic ModelRecruitingNCT06463392
• Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT06461624Phase 1
• GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Phase 2
• Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Phase 2
• Study of the Relationship Between Clinical, Imaging and Biological Data in Patients With Squamous Cell Carcinoma of the TongueRecruitingNCT06450080Not applicable
• Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular CarcinomaNot yet recruitingNCT06449846
• Quality of Life in Patients With Difficult-to-Treat Basal Cell Carcinoma: An Evaluation of Impact and Surgical Outcomes.RecruitingNCT06448936
• Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
• Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal CancerRecruitingNCT06445114Phase 2
• Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal CarcinomaRecruitingNCT06445088
• A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT06444009Phase 2
• Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06441019Phase 2
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingNCT06440057Phase 1/2
• Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 TrialRecruitingNCT06438627Phase 3
• Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell CarcinomaRecruitingNCT06436040
• Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract CarcinomaNot yet recruitingNCT06430827Phase 2
• Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06429865Not applicable
• [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT06428708Early Phase 1
• Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
• Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)RecruitingNCT06425146Not applicable
• PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7Not yet recruitingNCT06423144
• Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06422858Phase 2
• A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersRecruitingNCT06422403Phase 2
• OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.RecruitingNCT06421610Phase 1
• A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC PatientsRecruitingNCT06418659Early Phase 1
• Early Detection of Esophageal Squamous Cancer With the Capsule Sponge DeviceNot yet recruitingNCT06418516Not applicable
• Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)RecruitingNCT06418087Phase 2
• Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and TislelizumabRecruitingNCT06408584
• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1
• DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCCRecruitingNCT06397235Phase 2
• Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCCRecruitingNCT06397222Phase 2
• FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumRecruitingNCT06393816Phase 2
• International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal CarcinomatosisNot yet recruitingNCT06393543
• Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell CarcinomaRecruitingNCT06391879
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2
• Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06388135Phase 4
• Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular CarcinomaRecruitingNCT06384950Not applicable
• SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine CarcinomaRecruitingNCT06384482Phase 1
• Skin Cancer and Hyperthermia and RadiotherapyRecruitingNCT06384053Not applicable
• Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.RecruitingNCT06383780Phase 3

← Carcinoma overview